Estrace

Estrace is a prescription medication containing estradiol, a bioidentical form of estrogen, designed to address symptoms of menopause and hormonal deficiencies. As a trusted hormone replacement therapy (HRT), it delivers precise, consistent dosing to alleviate vasomotor symptoms, support urogenital health, and protect bone density. Manufactured under stringent pharmaceutical standards, Estrace offers a reliable option for women and transgender individuals seeking to manage estrogen deficiency under medical supervision.

Features

• Contains 17β-estradiol, a bioidentical estrogen identical to that produced by the human body
• Available in multiple formulations: oral tablets (0.5 mg, 1 mg, 2 mg) and topical cream (0.1 mg/g)
• Micronized estradiol for enhanced absorption and bioavailability
• Precisely calibrated dosing for individualized treatment regimens
• Manufactured in FDA-approved facilities ensuring purity and consistency

Benefits

• Effectively reduces the frequency and severity of hot flashes and night sweats
• Helps prevent postmenopausal osteoporosis by maintaining bone mineral density
• Alleviates symptoms of vulvar and vaginal atrophy, including dryness, itching, and discomfort
• Can improve mood stability and sleep quality in menopausal patients
• Supports the maintenance of healthy skin elasticity and collagen production
• Provides a bioidentical hormone option with predictable metabolic processing

Common use

Estrace is primarily prescribed for the management of moderate to severe vasomotor symptoms associated with menopause, such as hot flashes and night sweats. It is also indicated for the treatment of vulvar and vaginal atrophy, hypoestrogenism due to hypogonadism, castration, or primary ovarian failure, and for the prevention of postmenopausal osteoporosis. Additionally, it is used in gender-affirming hormone therapy for transgender women to promote feminization.

Dosage and direction

Dosage must be individualized based on patient response and treatment goals. For moderate to severe vasomotor symptoms: 1-2 mg orally daily, cyclically or continuously. For vulvar/vaginal atrophy: 2-4 g of cream intravaginally daily for 1-2 weeks, then gradually reduced to maintenance dose of 1 g 1-3 times weekly. For osteoporosis prevention: 0.5 mg orally daily. Tablets should be taken at the same time each day, with or without food. Topical cream should be measured using the applicator provided and inserted deeply into the vagina. Regular follow-up with a healthcare provider is essential for dosage adjustments.

Precautions

Patients should undergo complete medical and family history evaluation before initiation. Regular breast examinations, mammograms, and pelvic exams should be performed as clinically indicated. Blood pressure should be monitored periodically. Caution is advised in patients with conditions that might be influenced by fluid retention (asthma, epilepsy, migraine, cardiac or renal dysfunction). Estrace may cause photosensitivity—patients should use sun protection. Not recommended for use beyond the shortest duration consistent with treatment goals and risks.

Contraindications

Estrace is contraindicated in patients with known hypersensitivity to estradiol or any component of the formulation; undiagnosed abnormal genital bleeding; known or suspected estrogen-dependent neoplasia; active or history of arterial thromboembolic disease; active or recent venous thromboembolism; liver dysfunction or disease; known protein C, protein S, or antithrombin deficiency; and pregnancy.

Possible side effect

Common side effects include headache, breast tenderness or enlargement, nausea, abdominal cramps, bloating, vaginal bleeding or spotting, fluid retention, and mood changes. Less frequently reported effects include melasma, changes in libido, visual disturbances, and contact lens intolerance. Serious but rare adverse reactions include deep vein thrombosis, pulmonary embolism, stroke, myocardial infarction, gallbladder disease, and increased risk of endometrial cancer (in women with intact uterus without progestin opposition).

Drug interaction

Estrace may interact with CYP3A4 inducers (rifampin, carbamazepine, St. John’s wort) which can decrease estrogen levels. Concurrent use with thyroid hormone replacement therapy may increase thyroxine-binding globulin levels. Estrogens may reduce the effectiveness of anticoagulants and tamoxifen. May increase the toxicity of cyclosporine. Corticosteroid metabolism may be altered. Grapefruit juice may increase estrogen concentrations. Always inform your healthcare provider of all medications, including OTC drugs and supplements.

Missed dose

If a dose is missed, take it as soon as remembered unless it is almost time for the next dose. Do not double the dose to catch up. For vaginal cream: use the missed dose if remembered within 12 hours; otherwise, skip and resume regular schedule. Consistent dosing is important for maintaining stable hormone levels—consider setting reminders to improve adherence.

Overdose

Estrogen overdose may cause nausea, vomiting, breast tenderness, abdominal pain, drowsiness, or withdrawal bleeding. There is no specific antidote. Treatment should be symptomatic and supportive. Gastric lavage may be considered if ingestion was recent. Medical attention should be sought immediately, though serious acute toxicity is uncommon. Chronic overdose may lead to increased risk of estrogen-related adverse effects.

Storage

Store at controlled room temperature (20-25°C or 68-77°F). Keep container tightly closed. Protect from light and moisture. Do not freeze. Keep out of reach of children and pets. Do not use after expiration date printed on packaging. For vaginal cream: keep tube tightly closed when not in use. Do not store applicators in extreme temperatures.

Disclaimer

This information is for educational purposes only and does not constitute medical advice. Estrace is available by prescription only and should be used under appropriate medical supervision. Individual results may vary. Patients should consult with a qualified healthcare provider before starting, changing, or discontinuing any medication. The full prescribing information should be reviewed before use.

Reviews

“After struggling with severe hot flashes for two years, Estrace provided noticeable relief within three weeks. My sleep quality has significantly improved, and I appreciate having a bioidentical option.” - Maria T., 52

“As a transgender woman, Estrace has been instrumental in my feminization journey. My healthcare provider carefully monitors my levels, and the results have been both physically and emotionally affirming.” - Jessica L., 29

“I was hesitant about HRT due to family history, but my doctor recommended Estrace with regular monitoring. The low-dose tablet has effectively managed my symptoms without side effects.” - Susan W., 58

“The vaginal cream formulation resolved my atrophic symptoms that lubricants couldn’t address. The measured applicator makes dosing straightforward once you get used to it.” - Patricia R., 61